BioNTechBNTX
About: BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
Employees: 6,772
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.23% more ownership
Funds ownership: 21.34% [Q4 2024] → 21.57% (+0.23%) [Q1 2025]
7% less funds holding
Funds holding: 300 [Q4 2024] → 278 (-22) [Q1 2025]
13% less call options, than puts
Call options by funds: $137M | Put options by funds: $157M
18% less capital invested
Capital invested by funds: $5.78B [Q4 2024] → $4.71B (-$1.07B) [Q1 2025]
27% less repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 100
29% less funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 5 (-2) [Q1 2025]
30% less first-time investments, than exits
New positions opened: 40 | Existing positions closed: 57
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
Morgan Stanley Terence Flynn | 18%upside $133 | Overweight Maintained | 10 Jul 2025 |
HC Wainwright & Co. Robert Burns | 22%upside $138 | Buy Reiterated | 25 Jun 2025 |
Truist Securities Asthika Goonewardene | 37%upside $155 | Buy Reiterated | 3 Jun 2025 |
Goldman Sachs Asad Haider | 3%downside $110 | Neutral Initiated | 29 May 2025 |
JP Morgan Jessica Fye | 3%upside $116 | Neutral Maintained | 22 May 2025 |
Financial journalist opinion
Based on 8 articles about BNTX published over the past 30 days
